We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
Read MoreHide Full Article
Key Takeaways
PACB teamed with Blank Bio to generate HiFi long-read bulk RNA-seq data from tumors.
PACB work targets up to 100 fresh-frozen tumor samples across multiple cancer indications.
PACB says HiFi long reads can resolve complex tumor transcriptomes that conventional methods may miss.
Pacific Biosciences of California (PACB - Free Report) , also known as PacBio, recently entered a collaboration with Blank Bio, an applied AI research company focused on RNA foundation models for precision oncology. The collaboration accompanies PACB’s $7.2 million seed financing in Blank Bio to support model development and partnership expansion. Blank Bio will use PacBio’s HiFi long-read sequencing technology to generate bulk RNA sequencing data from patient tumor samples across multiple cancer indications.
PacBio Management noted that its HiFi long-read sequencing technology is built to resolve complex transcriptomes of tumors that conventional sequencing approaches may miss. The company underscored that Blank Bio’s foundation models show how high-resolution RNA sequencing and machine learning can strengthen precision oncology applications, including biomarker discovery, diagnostics and clinical trial design.
Likely Trend of PACB Stock Following the News
Following the announcement, the company's shares traded flat at yesterday’s closing. In the year-to-date period, the stock has declined 38.5% compared with the industry’s 18.8% fall. However, the S&P 500 has risen 9% in the same timeframe.
The collaboration with Blank Bio strengthens PacBio’s competitive standing in the oncology market. It also expands the use of its HiFi long-read sequencing technology in AI-driven precision medicine applications. Rising adoption of long-read sequencing across clinical research and biomarker development could support PacBio’s long-term growth in advanced sequencing technologies.
PACB currently has a market capitalization of $357.2 million.
Image Source: Zacks Investment Research
More on the News
Under the collaboration, Blank Bio will generate PacBio HiFi long-read, bulk RNA sequencing data from up to 100 fresh frozen tumor samples spanning multiple cancer types. Sequencing activities will be conducted at Seattle Children’s Research Institute using Kinnex RNA libraries on the SPTLabtech firefly+ platform.
Bulk RNA sequencing is being adopted ever more across oncology research as it provides insight into the molecular state of tumors at scalable costs. Traditional analysis methods often compress RNA-seq data into per-gene count summaries, limiting the ability to capture isoform diversity and patient-specific tumor biology.
PacBio believes its HiFi long-read sequencing technology will help address these limitations by delivering comprehensive transcriptomic information. The collaboration with Blank Bio is expected to support the development of next-generation AI models capable of improving patient stratification, biomarker discovery and clinical interpretation in oncology.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the U.S.-targeted DNA/RNA sequencing market was valued at $5.73 billion in 2026 and is expected to witness a CAGR of 19.2% through 2035.
Factors like the rising cancer incidences, increasing focus on oncology, growth of precision medicine and rising trend for early disease detection are boosting the market’s growth.
Other News
PacBio reported mixed first-quarter 2026 results, wherein earnings beat the Zacks Consensus Estimate while revenues missed the same. Stable revenues were supported by strong consumables demand, improving utilization trends and growth in the EMEA region, while operating losses narrowed due to lower expenses and restructuring benefits. During the quarter, PacBio strengthened its long-read sequencing business through collaborations with Basecamp Research, DNAstack and Lucid Genomics, expanded its SPRQ-Nx beta program and completed the sale of its short-read sequencing assets for approximately $48.1 million in net cash proceeds.
Some other top-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently carrying a Zacks Rank #2, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
Key Takeaways
Pacific Biosciences of California (PACB - Free Report) , also known as PacBio, recently entered a collaboration with Blank Bio, an applied AI research company focused on RNA foundation models for precision oncology. The collaboration accompanies PACB’s $7.2 million seed financing in Blank Bio to support model development and partnership expansion. Blank Bio will use PacBio’s HiFi long-read sequencing technology to generate bulk RNA sequencing data from patient tumor samples across multiple cancer indications.
PacBio Management noted that its HiFi long-read sequencing technology is built to resolve complex transcriptomes of tumors that conventional sequencing approaches may miss. The company underscored that Blank Bio’s foundation models show how high-resolution RNA sequencing and machine learning can strengthen precision oncology applications, including biomarker discovery, diagnostics and clinical trial design.
Likely Trend of PACB Stock Following the News
Following the announcement, the company's shares traded flat at yesterday’s closing. In the year-to-date period, the stock has declined 38.5% compared with the industry’s 18.8% fall. However, the S&P 500 has risen 9% in the same timeframe.
The collaboration with Blank Bio strengthens PacBio’s competitive standing in the oncology market. It also expands the use of its HiFi long-read sequencing technology in AI-driven precision medicine applications. Rising adoption of long-read sequencing across clinical research and biomarker development could support PacBio’s long-term growth in advanced sequencing technologies.
PACB currently has a market capitalization of $357.2 million.
Image Source: Zacks Investment Research
More on the News
Under the collaboration, Blank Bio will generate PacBio HiFi long-read, bulk RNA sequencing data from up to 100 fresh frozen tumor samples spanning multiple cancer types. Sequencing activities will be conducted at Seattle Children’s Research Institute using Kinnex RNA libraries on the SPTLabtech firefly+ platform.
Bulk RNA sequencing is being adopted ever more across oncology research as it provides insight into the molecular state of tumors at scalable costs. Traditional analysis methods often compress RNA-seq data into per-gene count summaries, limiting the ability to capture isoform diversity and patient-specific tumor biology.
PacBio believes its HiFi long-read sequencing technology will help address these limitations by delivering comprehensive transcriptomic information. The collaboration with Blank Bio is expected to support the development of next-generation AI models capable of improving patient stratification, biomarker discovery and clinical interpretation in oncology.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the U.S.-targeted DNA/RNA sequencing market was valued at $5.73 billion in 2026 and is expected to witness a CAGR of 19.2% through 2035.
Factors like the rising cancer incidences, increasing focus on oncology, growth of precision medicine and rising trend for early disease detection are boosting the market’s growth.
Other News
PacBio reported mixed first-quarter 2026 results, wherein earnings beat the Zacks Consensus Estimate while revenues missed the same. Stable revenues were supported by strong consumables demand, improving utilization trends and growth in the EMEA region, while operating losses narrowed due to lower expenses and restructuring benefits. During the quarter, PacBio strengthened its long-read sequencing business through collaborations with Basecamp Research, DNAstack and Lucid Genomics, expanded its SPRQ-Nx beta program and completed the sale of its short-read sequencing assets for approximately $48.1 million in net cash proceeds.
Pacific Biosciences of California, Inc. Price
Pacific Biosciences of California, Inc. price | Pacific Biosciences of California, Inc. Quote
PACB’s Zacks Rank & Other Key Picks
PacBio currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently carrying a Zacks Rank #2, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.